Movement Alert｜Viking Therapeutics Falls 8.01% in Regular Trading, Pulls Back Despite UBS Buy Initiation and Phase 3 VK2735 Progress

Market Focus10-17

On October 17, Viking Therapeutics fell 8.01% in Regular Trading, trading at $25.2 per share, with turnover of $124 million.

The most recent company-specific catalyst in public reports was UBS initiating coverage on October 15 with a Buy rating and a $94 price target, while analyst consensus compiled by FactSet also indicated a Buy rating with an average target price of $95.47.

Separately, Viking Therapeutics said on October 14 that it started the phase 3 program for oral VK2735 in adults with obesity, including one study in patients without type 2 diabetes and another in patients with type 2 diabetes. Both trials use percent change in body weight from baseline after 68 weeks as the primary endpoint. While those developments were positive on paper, the stock still moved lower in the latest session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment